West Pharmaceutical SVP exercises 383 RSUs

WEST PHARMACEUTICAL SERVICES INC senior vice president Rodolphe Jean Poussot reported equity compensation activity involving restricted stock units and common shares.

Rhea-AI Filing Summary

WEST PHARMACEUTICAL SERVICES INC senior vice president Rodolphe Jean Poussot reported equity compensation activity involving restricted stock units and common shares. On February 20, 2026, he exercised 383.382 restricted stock units, which converted into the same number of common shares at no cash cost.

Following this conversion, his directly held common stock position increased, then 129.545 shares of common stock were automatically withheld at $241.12 per share to cover tax obligations, leaving 561.235 common shares held directly after the transactions. Footnotes state that restricted stock units convert into common stock on a one-for-one basis and reference an earlier grant of 1,143 units vesting in three equal annual installments.

Insider Trade Summary

383.382 shares exercised/converted

Exercise 3 txns

Insider Poussot Rodolphe Jean

Role SVP, Strategy & Corporate Dev

Type	Security	Shares	Price	Value
Exercise	Rst. Stock Unit	383.382	$0.00	$0.00
Exercise	Common Stock	383.382	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	129.545	$241.12	$31K

Holdings After Transaction: Rst. Stock Unit — 383.359 contracts (Direct); Common Stock — 561.235 shares (Direct)

Footnotes (2)

1. F1. Restricted stock units convert into common stock on a one-for-one basis.
2. F2. On February 20, 2024, the reporting person was granted 1,143 restricted stock units, vesting in three equal annual installments (plus dividend equivalents).

FAQ

What insider transactions did WST executive Rodolphe Poussot report on this Form 4?

Rodolphe Poussot reported exercising 383.382 restricted stock units into common stock and a related tax withholding of 129.545 shares. These transactions reflect equity compensation activity, not an open-market stock purchase or discretionary sale.

How many West Pharmaceutical (WST) shares were withheld for taxes in this Form 4?

The filing shows 129.545 shares of West Pharmaceutical common stock withheld at $241.12 per share to satisfy tax obligations. This is coded as a tax-withholding disposition, not a market sale initiated by the executive.

What does the RSU conversion mean in West Pharmaceutical (WST) Poussot’s Form 4?

The Form 4 indicates 383.382 restricted stock units converted into an equal number of common shares at no cash cost. Footnotes explain restricted stock units convert one-for-one into common stock as they vest under a prior 1,143-unit grant.

Did the West Pharmaceutical (WST) executive buy or sell shares on the open market?

The transactions reflect an RSU conversion and tax withholding, not open-market trading. Shares were acquired through derivative exercise, while 129.545 shares were automatically delivered to cover tax liability under code F.

How many West Pharmaceutical (WST) shares does Poussot hold directly after these transactions?

After the reported transactions, Poussot directly holds 561.235 shares of West Pharmaceutical common stock. This figure comes from the post-transaction ownership line for the tax-withholding disposition entry.

What prior equity award is referenced in this West Pharmaceutical (WST) Form 4?

A footnote states that on February 20, 2024, Poussot was granted 1,143 restricted stock units. These vest in three equal annual installments, including dividend equivalents, and convert to common stock one-for-one as they vest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/23/2026 - 05:44 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Poussot Rodolphe Jean

(Last) (First) (Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON PA 19341

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Strategy & Corporate Dev

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/20/2026		M		383.382	A	(1)	690.78	D
Common Stock	02/20/2026		F		129.545	D	$241.12	561.235	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Rst. Stock Unit	(1)	02/20/2026		M			383.382	(2)	(2)	Common Stock	383.382	$0	383.359	D

Explanation of Responses:

1. Restricted stock units convert into common stock on a one-for-one basis.

2. On February 20, 2024, the reporting person was granted 1,143 restricted stock units, vesting in three equal annual installments (plus dividend equivalents).

	/s/ Louis Lalli, as an agent for Rodolphe J. Poussot	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.